Teva Pharmaceutical Industries (TEVJF) Invested Capital (2016 - 2025)
Historic Invested Capital for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $9.7 billion.
- Teva Pharmaceutical Industries' Invested Capital rose 3593.07% to $9.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.7 billion, marking a year-over-year increase of 3593.07%. This contributed to the annual value of $9.7 billion for FY2025, which is 3593.07% up from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Invested Capital stood at $9.7 billion for Q4 2025, which was up 3593.07% from $7.3 billion recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Invested Capital ranged from a high of $14.8 billion in Q2 2021 and a low of $6.7 billion during Q1 2025
- Moreover, its 5-year median value for Invested Capital was $9.8 billion (2023), whereas its average is $10.3 billion.
- Examining YoY changes over the last 5 years, Teva Pharmaceutical Industries' Invested Capital showed a top increase of 3593.07% in 2025 and a maximum decrease of 3690.46% in 2025.
- Teva Pharmaceutical Industries' Invested Capital (Quarter) stood at $12.7 billion in 2021, then fell by 15.49% to $10.7 billion in 2022, then fell by 8.49% to $9.8 billion in 2023, then dropped by 26.91% to $7.2 billion in 2024, then surged by 35.93% to $9.7 billion in 2025.
- Its Invested Capital stands at $9.7 billion for Q4 2025, versus $7.3 billion for Q3 2025 and $7.3 billion for Q2 2025.